Immune-mediated adverse rheumatic reactions following administration of immune checkpoint inhibitors

Immunotherapy with immune checkpoint inhibitors (ICIs) opens up new prospects in treatment of malignancies, although this novel therapy quite often results in development of immune-related adverse events (irAEs), which can limit their clinical use. IrAEs can affect almost any organ system, including...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	I. V. Menshikova, V. V. Strogonova
Format:	Artigo
Język:	Russo
Wydane:	IMA PRESS LLC 2020-09-01
Seria:	Научно-практическая ревматология
Hasła przedmiotowe:	immune checkpoint inhibitors immune-related adverse reactions cytotoxic t lymphocyte antigen-4 антиген-4 (ctla-4) programmed cell death protein 1 (pd-1)
Dostęp online:	https://rsp.mediar-press.net/rsp/article/view/2934
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!